vivoPharm deal brings new cancer models to US
Collaborates with preclinical oncology testing company in Germany
vivoPharm, a contract research organisation based in Australia that specialises in integrated preclinical services, has entered into a partnership with Experimental Pharmacology & Oncology Berlin-Buch (EPO), a leading preclinical oncology testing company in Germany.
Under the co-marketing agreement vivoPharm will offer for the first time to cancer researchers in the US EPO’s collection of primary patient-derived tumours.
vivoPharm says the EPO tumours are the ‘newest, most clinically relevant models for validating drug candidates for cancer treatment’.
The company has been working with predictive tumour models for more than a decade and says the agreement with EPO adds another dimension to its service portfolio.
US-based drug developers can partner with vivoPharm to characterise their own therapeutic compounds using vivoPharm’s highly specialised orthotopic cancer models and advanced research models directly derived from patients.
Dr Ralf Brandt, chief executive and md of vivoPharm said the company is committed to ‘using its global reach to identify innovative research methods and introduce them to the US market’ and the agreement with EPO is a continuation of this commitment.
